Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Emergent BioSolutions Inc. (EBSI) (NYSE: EBS)

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. *

 

Period Start 2004-03-01 established
  Group Emergent BioSolutions (Group)
Products Industry BIOTECH
  Industry 2 vaccine
     
Region Region Gaithersburg, MD
  Country United States (USA)
  Street 2273 Research Boulevard, Suite 400
  City 20850 Rockville, MD
  Tel +1-301-795-1800
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Annual sales 182,915,000 (revenue, total, consolidated (2007) 2007-12-31)
  Profit 22,936,000 (2007-12-31)
  Cash 105,730,000 (2007-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2020-09-18

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Emergent BioSolutions (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top